Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.


News Release

 View printer-friendly version

Charles River Laboratories Announces Third-Quarter 2002 Results, Provides Positive Outlook for 2002 and 2003, and Elects New Board Member
WILMINGTON, Mass., Oct 29, 2002 (BUSINESS WIRE) -- Third-Quarter Income Before Extraordinary Item Up 60% and EPS Up 50% on Net Sales Increase of 14%

Total Year 2002 EPS Guidance Raised to $1.41-$1.43 Strong Sales and EPS Growth Expected in 2003

Douglas E. Rogers Elected to Board of Directors

Charles River Laboratories International, Inc. (NYSE:CRL) today reported third-quarter 2002 income before extraordinary item of $18.9 million, a 60.2% increase over the $11.8 million reported in the third quarter of 2001. Earnings per share rose 50.0% to $0.39 per diluted share from $0.26 per diluted share reported last year. Net sales in the third quarter were $141.4 million compared to $123.7 million reported in 2001, an increase of 14.3%. Net income for the third quarter was $18.5 million, or $0.38 per diluted share, including an extraordinary charge of $0.4 million, or $0.01 per diluted share, for termination of a $30.0 million revolving credit facility. Interest expense for the third quarter was $1.9 million compared to $5.1 million in the third quarter of 2001.

Operating income in the third quarter of 2002 rose 35.4% to $32.5 million from $24.0 million in the same period in 2001. The Company's operating margin rose to 23.0%, a 360 basis point increase over the 19.4% margin achieved in the third quarter of last year, reflecting higher sales in both the research models and biomedical products and services businesses and operating efficiencies resulting from the increased volume.

Effective January 1, 2002, the Company adopted Statement of Financial Accounting Standards No. 142 (SFAS 142), "Goodwill and Other Intangible Assets." The effect of this change amounted to $0.02 per diluted share on the Company's third-quarter 2002 results and $0.06 per diluted share for the year to date.

James C. Foster, Chairman, President and Chief Executive Officer said, "For the ninth consecutive quarter since going public, Charles River has again delivered substantial growth in sales, margins, and earnings per share. Our solid and consistent financial performance reflects the leading share position we hold in a number of attractive markets and the strength of the growing drug discovery and development market.

Mr. Foster added, "We have built a strong and diverse portfolio of businesses that provide a comprehensive array of services in the non-clinical drug development field. We're extremely well positioned to be a key, strategic partner with our customers as they increasingly outsource the discovery and development of new drugs, diagnostics, and medical devices. We expanded the scale of our service offerings with the October 1, 2002, acquisition of Springborn Laboratories which strengthens both our geographic and client access position in the toxicology market. The October 2, 2002, addition of Charles River Proteomics Services, our 80/20 joint venture with Proteome Systems Ltd, positions us to become a market leader in the field of providing proteomics services."

Third-quarter 2002 net sales for the Research Models segment of the business were $56.8 million compared to $50.6 million last year. The 12.1% gain reflected increased customer demand for animal research models and higher sales of specialty models for pre-clinical drug development work. Significantly higher sales yielded a gross margin of 44.7% compared to 40.5% in the third quarter of last year. The sales increase also generated operating efficiencies which resulted in a 38.0% increase in operating income, to $18.6 million in the third quarter with an operating margin of 32.8%, compared to last year's $13.5 million and 26.6%.

Mr. Foster said, "Demand for research models continues to grow steadily. As pharmaceutical and biotech companies increase the number of compounds they are developing, there is a corresponding increase in their use of research models, particularly the specialty models used in research on diabetes, cardiovascular disease, and cancer as well as standard outbred strains used for drug safety testing. In order to keep pace with the demand, we have added to North American production capacity for the first time in over a decade."

Net sales for the Biomedical Products and Services segment rose 15.8% in the third quarter, to $84.6 million from $73.0 million in the same period last year. The Company's discovery services business, which includes transgenic, laboratory testing, and contract staffing services, had significant sales growth in the quarter, led by transgenic services. Sales for the development services business, which includes the entire range of pre-clinical drug testing services, also increased, with strong growth of drug safety assessment and biosafety testing for biotech companies producing drugs derived from human proteins. BioLabs, the Irish-based human and animal health sciences company acquired in June 2002, is performing well and in line with our expectations.

The third-quarter 2002 gross margin for the Biomedical Products and Services segment was 33.2%, a 210 basis point increase over the 31.1% achieved in last year's third quarter. Segment operating income rose 27.6% to $17.1 million from $13.4 million last year and the operating margin increased to 20.2% from 18.3%.

Nine-Month Results

For the first nine months of 2002, income before extraordinary items rose 71.9% to $50.9 million from $29.6 million in the same period last year. Earnings per share were $1.06 per diluted share, a 55.9% increase over last year's $0.68 per diluted share. These results were driven by a 21.2% increase in net sales, to $411.7 million from $339.5 million last year.

Income before extraordinary items also improved due to a reduction in interest expense resulting from the issuance of $185.0 million of senior convertible debentures with an interest rate of 3.5% and the subsequent early retirement of the Company's 13.5% senior subordinated notes and its senior secured term loan facilities. Interest expense declined to $9.2 million in the nine-month period from $18.4 million in the same period last year.

Operating income for the nine-month period was $91.3 million, a 34.5% increase over the $67.9 million reported in the same period in 2001. The Company's operating margin rose to 22.2% compared to 20.0% in the third quarter of last year, reflecting higher sales and the resulting operating efficiencies and the effect of the adoption of SFAS 142.


The following forward-looking guidance is based on current exchange rates.

The Company now anticipates that net sales for the fourth quarter of 2002 will be approximately 15.0% higher than last year's fourth quarter due to continued growth in both the Research Models and Biomedical Products and Services segments. Diluted earnings per share are expected to be in a range of $0.35 to $0.37, reflecting higher sales and operating efficiencies. Fourth-quarter earnings per share are typically slightly lower than third-quarter, reflecting industry seasonality in the Research Models business segment. For the full year, the Company expects earnings per diluted share before extraordinary items of between $1.41 and $1.43, more than a 50.0% increase over 2001 results.

In 2003, the Company expects to see continuing growth in its business. Spending on pre-clinical research and development by the pharmaceutical and biotech industry is expected to increase and outsourcing of these services will continue. For these reasons, the Company expects net sales to advance by more than 15.0% and earnings per diluted share to grow at a faster rate than sales.

Rogers Elected to Board of Directors

At Charles River Laboratories' Board of Directors meeting on October 23, 2002, Douglas E. Rogers was elected a member of the Board. Mr. Rogers, who previously served on the Board from 1999 until 2001, has extensive experience in investment banking for the health care industry, most recently with Credit Suisse First Boston. Mr. Foster said, "We're very pleased to have Doug rejoin our Board. He worked with us throughout the LBO and public offering and has invaluable knowledge of the capital markets and of our industry. Doug further strengthens our already independent Board and we look forward to working with him again."


Charles River Laboratories has scheduled a live webcast on Wednesday, October 30, at 8:30 a.m. EST to discuss matters relating to this press release. To participate, please go to, Investor Relations, and select the webcast link. The webcast will be available until 5:00 p.m. EST on November 6, 2002.

Charles River Laboratories, based in Wilmington, Massachusetts, is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. The Company is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies. The Company also offers a broad and growing portfolio of biomedical products and services that enable customers to reduce cost, increase speed, and enhance productivity and effectiveness in drug discovery and development. Charles River's customer base spans over 50 countries, and includes all of the major pharmaceutical and biotechnology companies, as well as many leading hospitals and academic institutions. The Company operates 76 facilities in 16 countries worldwide.

Caution Concerning Forward-Looking Statements. This document includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "estimate," "plan," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on management's current expectations, and involve a number of risks and uncertainties that could cause actual results to differ materially from those stated or implied by the forward-looking statements, and the company expressly does not undertake any duty to update forward-looking statements, which speak only as of the date of this document. Those risks and uncertainties include, but are not limited to: acquisition integration risks; special interest groups; contaminations; industry trends; new displacement technologies; outsourcing trends; USDA and FDA regulation; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; and changes in generally accepted accounting principles. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in the Company's registration statement on Form S-3 as filed on April 9, 2002, with the Securities and Exchange Commission.

           (dollars in thousands except for per share data)
                        Three Months Ended        Nine Months Ended
                      Sept. 28,    Sept. 29,    Sept. 28,   Sept. 29,
                        2002         2001         2002         2001
Total Net Sales      $ 141,364    $ 123,685    $ 411,685    $ 339,536
Cost of products
 sold and services
 provided               87,889       80,474      255,851      215,893
Gross margin            53,475       43,211      155,834      123,643
Selling, general
 and administrative     20,023       17,016       62,329       49,761
Amortization of
 goodwill and
 intangibles               933        2,183        2,194        6,004
Operating income        32,519       24,012       91,311       67,878
Interest income
 (expense)              (1,862)      (5,096)      (7,515)     (17,395)
Other income (expense)     (48)          83        1,029          516
Income before taxes,
 minority interests,
 earnings from
 equity investments
 and extraordinary
 item                   30,609       18,999       84,825       50,999
Provision for income
 taxes                  11,041        6,677       32,185       19,891
Income before
 minority interests,
 earnings from
 equity investments
 and extraordinary
 item                   19,568       12,322       52,640       31,108
Minority interests        (717)        (643)      (2,098)      (1,859)
Earnings from equity
 investments                57          126          316          345
Net income before
 extraordinary item     18,908       11,805       50,858       29,594
Extraordinary loss,
 net of tax benefit       (377)      (1,284)     (18,231)      (3,104)
Net income             $ 18,531    $ 10,521     $ 32,627     $ 26,490
Earnings per common
 share before
 extraordinary item
  Basic                 $ 0.42       $ 0.27       $ 1.14       $ 0.74
  Diluted               $ 0.39       $ 0.26       $ 1.06       $ 0.68
Earnings per common
 share after
 extraordinary item
  Basic                 $ 0.41       $ 0.24       $ 0.73       $ 0.66
  Diluted               $ 0.38       $ 0.23       $ 0.70       $ 0.61
Weighted average
 number of common
 shares outstanding
 before and after
 extraordinary item
  Basic             44,916,369   43,054,478   44,583,773   39,953,655
  Diluted           51,384,534   45,679,127   50,680,170   43,429,162
                        (dollars in thousands)
                                         September 28,    December 29,
                                            2002              2001
Current assets
   Cash and cash equivalents             $ 117,389          $ 58,271
   Trade receivables                        98,718            98,478
   Inventories                              41,921            39,056
   Other current assets                     15,892            14,349
      Total current assets                 273,920           210,154
Property, plant and equipment, net         174,548           155,919
Goodwill, net                               78,650            52,087
Other intangibles, net                      28,274            38,287
Deferred tax asset                          77,128            87,781
Other assets                                23,788            27,134
      Total assets                       $ 656,308         $ 571,362
Liabilities and Shareholders' Equity
Current liabilities
   Accounts payable                       $ 10,917          $ 13,868
   Accrued compensation                     28,185            25,736
   Other current liabilities                61,797            58,928
      Total current liabilities            100,899            98,532
Long-term debt                             188,512           155,506
Other long-term liabilities                 17,122            14,826
      Total liabilities                    306,533           268,864
Minority interests                          16,935            12,988
Total shareholders' equity                 332,840           289,510
Total liabilities and shareholders'
 equity                                  $ 656,308         $ 571,362
                        (dollars in thousands)
                        Three Months Ended        Nine Months Ended
                       Sept. 28,   Sept. 29,    Sept. 28,    Sept. 29,
                         2002         2001        2002         2001
Research Models
  Net sales            $56,771      $50,647     $170,214     $148,134
  Gross margin          25,375       20,511       77,534       61,975
  Gross margin as
   a % of sales           44.7%        40.5%        45.6%        41.8%
  Operating income      18,596       13,476       57,121       40,428
  Operating income
   as a % of sales        32.8%        26.6%        33.6%        27.3%
   amortization          2,472        2,474        7,013        7,210
  Capital expenditures   2,954        2,309        9,493        6,701
Biomedical Products
 and Services
  Net sales            $84,593      $73,038     $241,471     $191,402
  Gross margin          28,100       22,700       78,300       61,668
  Gross margin as
   a % of sales           33.2%        31.1%        32.4%        32.2%
  Operating income      17,093       13,394       47,531       34,350
  Operating income
   as a % of sales        20.2%        18.3%        19.7%        17.9%
   amortization          3,859        4,738       10,368       12,031
  Capital expenditures   4,354        6,495       12,121       13,829
Unallocated Corporate
 Overhead              ($3,170)     ($2,858)    ($13,341)     ($6,900)
  Net sales           $141,364     $123,685     $411,685     $339,536
  Gross margin          53,475       43,211      155,834      123,643
  Gross margin
   as a % of sales        37.8%        34.9%        37.9%        36.4%
  Operating income      32,519       24,012       91,311       67,878
  Operating income
   as a % of sales        23.0%        19.4%        22.2%        20.0%
   amortization          6,331        7,212       17,381       19,241
  Capital expenditures   7,308        8,804       21,614       20,530
Charles River Laboratories International, Inc.
Susan E. Hardy, 978/658-6000, ext. 1616
Director, Investor Relations

Featured Report

2019 Annual Report (PDF)